

Global Kidney Cancer Drugs Market Size Study, by Type (Renal Cell Carcinoma (RCC), Transitional Cell Cancer, Wilms Tumor, Renal Sarcoma), by Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), by Drug Class (Angiogenesis Inhibitors, Monoclonal Antibodies, mTOR Inhibitors, Cytokine Immunotherapy), by Route of Administration (Oral, Intravenous, Subcutaneous), by End Use (Hospital Pharmacies, Retail Pharmacies, Others), and Regional Forecasts 2022–2032

<https://marketpublishers.com/r/GE158DBB8385EN.html>

Date: January 2025

Pages: 285

Price: US\$ 3,750.00 (Single User License)

ID: GE158DBB8385EN

Abstracts

The global kidney cancer drugs market was valued at USD 6.25 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.9% over the forecast period from 2024 to 2032. This growth is primarily driven by advancements in immunotherapy and targeted therapies, which are revolutionizing treatment outcomes for patients with kidney cancer. Additionally, the increasing prevalence of renal cell carcinoma (RCC), coupled with the rise in healthcare expenditure, is fostering market growth.

Renal Cell Carcinoma (RCC) is the leading type of kidney cancer, contributing to 85.8% of market revenue in 2023. This is attributed to aging demographics, lifestyle-related risk factors, and improvements in diagnostic techniques enabling early detection. Immunotherapies and targeted treatments are anticipated to expand further, offering a more patient-centric approach with minimized side effects compared to traditional chemotherapies.

Geographically, North America dominated the kidney cancer drugs market in 2023, supported by robust healthcare infrastructure and access to cutting-edge treatments. The Asia-Pacific region, however, is projected to grow at the fastest rate, owing to increasing healthcare access and awareness campaigns. Rising adoption of biosimilars and innovative drug pipelines also present promising opportunities for market players in emerging economies.

Major market players included in this report are:

Astellas Pharma Inc.

AstraZeneca PLC

Bayer AG

Bristol-Myers Squibb Company

Eisai Co., Ltd.

F. Hoffmann-La Roche Ltd.

GSK plc

Helsinn Healthcare SA

Johnson & Johnson Services, Inc.

Merck & Co., Inc.

Novartis AG

The detailed segments and sub-segments of the market are explained below:

By Type

Renal Cell Carcinoma (RCC)

Transitional Cell Cancer

Wilms Tumor

Renal Sarcoma

By Therapy

Targeted Therapy

Immunotherapy

Chemotherapy

Other Therapies

By Drug Class

Angiogenesis Inhibitors

Monoclonal Antibodies

mTOR Inhibitors

Cytokine Immunotherapy (IL-2)

Other Drug Classes

By Route of Administration

Oral

Intravenous

Subcutaneous

By End Use

Hospital Pharmacies

Retail Pharmacies

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Middle East & Africa

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market estimates & forecasts for 10 years from 2022 to 2032.

Annualized revenues and regional-level analysis for each market segment.

Detailed analysis of geographical landscape with country-level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approaches.

Analysis of the competitive structure of the market.

Demand-side and supply-side analysis of the market.

Contents

CHAPTER 1. GLOBAL KIDNEY CANCER DRUGS MARKET EXECUTIVE SUMMARY

- 1.1. Global Kidney Cancer Drugs Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Type
 - 1.3.2. By Therapy
 - 1.3.3. By Drug Class
 - 1.3.4. By Route of Administration
 - 1.3.5. By End Use
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL KIDNEY CANCER DRUGS MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Consumer's Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Regulatory Frameworks
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Environmental Considerations
 - 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL KIDNEY CANCER DRUGS MARKET DYNAMICS

3.1. Market Drivers

- 3.1.1. Rising Kidney Cancer Incidence Rates
- 3.1.2. Advancements in Immunotherapy and Targeted Therapy
- 3.1.3. Increase in Healthcare Spending and Awareness Campaigns

3.2. Market Challenges

- 3.2.1. High Costs and Side Effects of Kidney Cancer Drugs
- 3.2.2. Regulatory Complexities in Drug Approvals

3.3. Market Opportunities

- 3.3.1. Emerging Markets with Undiagnosed Populations
- 3.3.2. Expansion of Biosimilars

CHAPTER 4. GLOBAL KIDNEY CANCER DRUGS MARKET INDUSTRY ANALYSIS

4.1. Porter's 5 Force Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunities

4.4. Top Winning Strategies

4.5. Disruptive Trends

4.6. Industry Expert Perspective

4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE & FORECASTS BY TYPE (2022–2032)

5.1. Segment Dashboard

5.2. Global Kidney Cancer Drugs Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

5.2.1. Renal Cell Carcinoma (RCC)

5.2.2. Transitional Cell Cancer

5.2.3. Wilms Tumor

5.2.4. Renal Sarcoma

CHAPTER 6. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE & FORECASTS BY THERAPY (2022–2032)

6.1. Segment Dashboard

6.2. Global Kidney Cancer Drugs Market: Therapy Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

6.2.1. Targeted Therapy

6.2.2. Immunotherapy

6.2.3. Chemotherapy

6.2.4. Other Therapies

CHAPTER 7. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE & FORECASTS BY DRUG CLASS (2022–2032)

7.1. Segment Dashboard

7.2. Global Kidney Cancer Drugs Market: Drug Class Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

7.2.1. Angiogenesis Inhibitors

7.2.2. Monoclonal Antibodies

7.2.3. mTOR Inhibitors

7.2.4. Cytokine Immunotherapy (IL-2)

7.2.5. Other Drug Classes

CHAPTER 8. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE & FORECASTS BY ROUTE OF ADMINISTRATION (2022–2032)

8.1. Segment Dashboard

8.2. Global Kidney Cancer Drugs Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

8.2.1. Oral

8.2.2. Intravenous

8.2.3. Subcutaneous

CHAPTER 9. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE & FORECASTS BY END USE (2022–2032)

9.1. Segment Dashboard

9.2. Global Kidney Cancer Drugs Market: End Use Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

9.2.1. Hospital Pharmacies

9.2.2. Retail Pharmacies

9.2.3. Others

CHAPTER 10. GLOBAL KIDNEY CANCER DRUGS MARKET SIZE & FORECASTS BY REGION (2022–2032)

10.1. North America Kidney Cancer Drugs Market

10.1.1. U.S. Kidney Cancer Drugs Market

10.1.2. Canada Kidney Cancer Drugs Market

10.1.3. Mexico Kidney Cancer Drugs Market

10.2. Europe Kidney Cancer Drugs Market

10.2.1. UK Kidney Cancer Drugs Market

10.2.2. Germany Kidney Cancer Drugs Market

10.2.3. France Kidney Cancer Drugs Market

10.2.4. Italy Kidney Cancer Drugs Market

10.2.5. Spain Kidney Cancer Drugs Market

10.3. Asia Pacific Kidney Cancer Drugs Market

10.3.1. China Kidney Cancer Drugs Market

10.3.2. Japan Kidney Cancer Drugs Market

10.3.3. India Kidney Cancer Drugs Market

10.3.4. Australia Kidney Cancer Drugs Market

10.3.5. South Korea Kidney Cancer Drugs Market

10.4. Latin America Kidney Cancer Drugs Market

10.4.1. Brazil Kidney Cancer Drugs Market

10.4.2. Argentina Kidney Cancer Drugs Market

10.5. Middle East & Africa Kidney Cancer Drugs Market

10.5.1. Saudi Arabia Kidney Cancer Drugs Market

10.5.2. South Africa Kidney Cancer Drugs Market

CHAPTER 11. COMPETITIVE INTELLIGENCE

- 11.1. Key Company SWOT Analysis
 - 11.1.1. Astellas Pharma Inc.
 - 11.1.2. F. Hoffmann-La Roche Ltd.
 - 11.1.3. Merck & Co., Inc.
- 11.2. Top Market Strategies
- 11.3. Company Profiles

CHAPTER 12. RESEARCH PROCESS

- 12.1. Research Process Overview
 - 12.1.1. Data Mining
 - 12.1.2. Analysis
 - 12.1.3. Market Estimation
 - 12.1.4. Validation

12. LIST OF TABLES

- 1. GLOBAL KIDNEY CANCER DRUGS MARKET BY TYPE, 2022–2032 (USD BILLION)**
- 2. GLOBAL KIDNEY CANCER DRUGS MARKET BY THERAPY, 2022–2032 (USD BILLION)**
- 3. GLOBAL KIDNEY CANCER DRUGS MARKET BY DRUG CLASS, 2022–2032 (USD BILLION)**
- 4. GLOBAL KIDNEY CANCER DRUGS MARKET BY ROUTE OF ADMINISTRATION, 2022–2032 (USD BILLION)**
- 5. GLOBAL KIDNEY CANCER DRUGS MARKET BY END USE, 2022–2032 (USD BILLION)**
- 6. REGIONAL REVENUE SHARE ANALYSIS, 2022–2032**

...

This list is not complete. Final report does contain more than 100 tables.

12. LIST OF FIGURES

Global Kidney Cancer Drugs Market Size Study, by Type (Renal Cell Carcinoma (RCC), Transitional Cell Cancer, W...

1. GLOBAL KIDNEY CANCER DRUGS MARKET, RESEARCH METHODOLOGY OVERVIEW

2. REVENUE FORECAST ANALYSIS, 2022 & 2032 (USD BILLION)

3. REGIONAL MARKET SHARE SNAPSHOT, 2022 & 2032

4. THERAPY REVENUE SHARE BY REGION, 2022 & 2032

...

This list is not complete. Final report does contain more than 50 figures.

I would like to order

Product name: Global Kidney Cancer Drugs Market Size Study, by Type (Renal Cell Carcinoma (RCC), Transitional Cell Cancer, Wilms Tumor, Renal Sarcoma), by Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), by Drug Class (Angiogenesis Inhibitors, Monoclonal Antibodies, mTOR Inhibitors, Cytokine Immunotherapy), by Route of Administration (Oral, Intravenous, Subcutaneous), by End Use (Hospital Pharmacies, Retail Pharmacies, Others), and Regional Forecasts 2022–2032

Product link: <https://marketpublishers.com/r/GE158DBB8385EN.html>

Price: US\$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE158DBB8385EN.html>